Image of CSO Jakob Lindberg's tattoo of the melflufen molecule.

Science news

Filter by year

Oncopeptides presents new data highlighting treatment benefits of Pepaxti in high-risk multiple myeloma patients at the COMy Congress

May 16, 2024
Oncopeptides today announces that new scientific data on melflufen, branded in Europe as Pepaxti, has been accepted at the 10th annual World Congress on Controversies in Multiple Myeloma (COMy), to be held on May 23-26.
Read more

Oncopeptides’ PORT study shows peripheral administration of Pepaxti being equally safe as central venous administration

March 1, 2024
Oncopeptides today announces that a new article analyzing scientific data on melflufen, marketed in Europe as Pepaxti, was recently published in the peer-reviewed medical journal Clinical Lymphoma, Myeloma and Leukemia.
Read more

Pepaxti provides sustained health related Quality of Life OCEAN study shows, article published in Haematologica

February 29, 2024
Oncopeptides today announces that a new article analyzing health-related quality of life in patients treated with melflufen, marketed in Europe as Pepaxti, has been published in Haematologica.
Read more

Type IB variation process finalized – original indication remains with peripheral administration included

February 7, 2024
Oncopeptides recently received a favorable opinion from EMA to revert back to the originally approved indication for Pepaxti. This means that the previously communicated decision to opt out of the process to extend the indication has now been fully realized.
Read more

Article with exploratory alkylator-refractory subgroup analysis from Oncopeptides’ OCEAN study observing longer PFS and OS in melflufen vs. pomalidomide published in European Journal of Haematology

November 17, 2023
November 17, 2023 - The results further demonstrate efficacy and consistent safety profile in patients with alkylator-refractory disease.
Read more

Oncopeptides selected to present additional data from OCEAN study at the American Society of Hematology meeting

November 13, 2023
November 13, 2023. Long-term outcomes from its Phase 3 OCEAN study has been accepted as a poster and will be presented at ASH in San Diego, December 9-12.
Read more

Oncopeptides publishes article in the Journal of Clinical Pharmacology

October 23, 2023
October 23, 2023. A new article on the Phamacokinetics and metabolism of melflufen, marketed in Europe as Pepaxti, in patients with Relapsed Refractory Multiple Myeloma.
Read more

Oncopeptides publishes article on NK cell engagers in New Biotechnology

September 12, 2023
A new article, describing a set of affibody-based NK cell engagers using B cell maturation antigen (BCMA) as a model antigen for targeting of multiple myeloma, has been published online ahead of the November issue of New Biotechnology, the official journal of the European Federation of Biotechnology (EFB). Among the highlights of the article, dual engagers are found effective in activating resting NK cells and inducing a BCMA-dependent killing of MM cells.
Read more

Oncopeptides publishes two articles with results from ANCHOR and LIGHTHOUSE studies in Haematologica

September 4, 2023
Stockholm – September 4, 2023 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that two new articles with scientific data on melflufen, marketed in Europe as Pepaxti, has been published in Haematologica, a publication reporting on important findings...
Read more